Table 5.
Univariate predictors of time to occurrence of liver diseasea and time to abnormal ALT and ALP for women with ICP
| Covariates | Time to liver disease |
Time to ALT >25 U/L |
Time to ALP >140 U/L |
||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Hispanic | 1.2 | 0.85–14.2 | 0.08 | 1.7 | 1.0–2.9 | 0.04 | 2.4 | 1.1–5.2 | 0.02 |
| AMA (≥35 yr) | 2.2 | 1.5–4.1 | 0.02 | 1.1 | 0.73–1.8 | 0.57 | 0.6 | 0.28–1.1 | 0.09 |
| GDM | 1.3 | 0.60–2.6 | 0.55 | 0.82 | 0.51–1.3 | 0.41 | 0.74 | 0.40–1.4 | 0.74 |
| Overweightor higher (BMI >25 kg/m2) | 2.4 | 1.4–4.3 | <0.01 | 1.1 | 083–1.4 | 0.53 | 1.2 | 0.57–1.2 | 0.82 |
| Bile acid levels >50 μmol/L | 0.61 | 0.34–1.1 | 0.10 | 1.1 | 0.80–1.4 | 0.63 | 1.5 | 1.0–2.1 | 0.03 |
| ALT >50 U/L in pregnancy | 0.86 | 0.52–1.4 | 0.56 | 1.3 | 1.0–1.8 | 0.009 | 1.3 | 0.92–1.9 | 0.13 |
| ALT >25 U/L in pregnancy | 1.1 | 0.55–2.3 | 0.74 | 1.4 | 0.92–2.1 | 0.11 | 1.4 | 0.82–2.4 | 0.21 |
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, advanced maternal age; BMI, body mass index; CI, confidence interval; GDM, gestational diabetes; HR, hazard ratio; ICP, intrahepatic cholestasis of pregnancy.
a
Liver disease defined by chart review and imaging findings.